J. Schoemaker

Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder

J. Schoemaker, Dieter Naber, Peter Vrijland et al. · Pharmacopsychiatry · 2010 · 85 citations

Medicine, Pharmacology, Psychiatry +14

Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms

Rik de Greef, Alan Maloney, Per Olsson et al. · The AAPS Journal · 2010 · 60 citations · Full text

Medicine, Neuroscience, Pharmacology +14

The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia

J. Schoemaker, Wim T. Jansen, J. Schipper et al. · Journal of Clinical Psychopharmacology · 2014 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of the Glycine Transporter‐1 Inhibitor Org 25935 for the Prevention of Relapse in Alcohol‐Dependent Patients: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Andrea de Bejczy, Kari R. Nations, Armin Szegedi et al. · Alcoholism Clinical and Experimental Research · 2014 · 32 citations

Medicine, Pharmacology, Psychiatry +17

Long-Term Efficacy and Safety of Asenapine or Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder: An Extension Study

J. Schoemaker, Peter Vrijland, Dieter Naber et al. · Pharmacopsychiatry · 2012 · 27 citations

Pharmacy, Pharmacotherapy, Psychiatry +17